The Keloids drugs in development market research report provides comprehensive information on the therapeutics under development for Keloids, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Keloids. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Keloids and features dormant and discontinued products.
GlobalData tracks 11 drugs in development for Keloids by ten companies/universities/institutes. The top development phase for Keloids is phase ii with three drugs in that stage. The Keloids pipeline has 11 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Keloids pipeline products market are: Thirona Bio, MedRegen and Sirnaomics.
The key targets in the Keloids pipeline products market include Prostaglandin G/H Synthase 2, Phosphodiesterase 4, and Transforming Growth Factor Beta 1 Proprotein.
The key mechanisms of action in the Keloids pipeline product include Calcineurin Inhibitor with one drug in Phase I. The Keloids pipeline products include seven routes of administration with the top ROA being Topical and four key molecule types in the Keloids pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.
Keloids overview
Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged scars, which can become irritated from friction against clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroids, radiation, surgical removal, and silicone gel or patches.
For a complete picture of Keloids’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
